Psoriasis Treatment Market By Treatment Type (Topical Therapies, Systemic Therapies, Biologic Therapies, Oral Small-Molecule Therapies, Phototherapy); By Drug Class (Interleukin Inhibitors, TNF Inhibitors, TYK2 Inhibitors, PDE4 Inhibitors, Conventional Immunosuppressants, Retinoids, Corticosteroids, Vitamin D Analogues); By Application (Plaque Psoriasis, Psoriatic Arthritis, Generalized Pustular Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Erythrodermic Psoriasis); By Route of Administration (Oral, Injectable, Topical); By End User (Hospitals, Dermatology Clinics, Specialty Clinics, Homecare Settings, Retail and Specialty Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Psoriasis Treatment Market: Oral IL-23 and TYK2 Therapies Challenge Injection-Led Biologic Growth

The Global Psoriasis Treatment Market was valued at USD 35.13 billion in 2025 and is projected to reach USD 61.08 billion by 2032, growing at a CAGR of 8.1%, according to Strategic Market Research.

 

New oral psoriasis therapies are achieving skin-clearance rates that are increasingly comparable with injectable biologics. Johnson & Johnson’s March 2026 approval of icotrokinra introduced the first oral peptide targeting the IL-23 receptor, while Takeda’s zasocitinib and Alumis’ envudeucitinib have produced late-stage results that could expand the high-efficacy oral segment.

 

Injectable IL-17 and IL-23 inhibitors remain difficult to displace because they deliver rapid and durable clearance in moderate-to-severe plaque psoriasis, scalp disease, difficult anatomical sites, and psoriatic arthritis. Oral products must compete on efficacy, safety monitoring, treatment persistence, injection avoidance, dosing frequency, joint involvement, insurance coverage, and cost relative to originator biologics and biosimilars.

 

Topical therapies serve the largest patient population, but biologics and advanced oral medicines account for a greater share of treatment spending. Continuous use in moderate-to-severe disease, special-area involvement, topical-treatment failure, and psoriatic arthritis supports recurring revenue well beyond the number of patients receiving advanced therapy.

 

Diagnosed Prevalence Overstates the Premium Treatment Pool

The Global Psoriasis Atlas estimates approximately 43 million physician- or dermatologist-diagnosed cases worldwide, with an uncertainty range of 27 million to 91 million. Self-reported prevalence is much higher at approximately 102 million people, but the figures use different case definitions and should not be combined. Population-level epidemiological evidence is available for only 41 of more than 220 countries and territories, leaving substantial uncertainty across emerging markets.

Adult physician-diagnosed prevalence ranges from about 0.15% in Eastern Sub-Saharan Africa to 3.68% in Australasia. A nationally representative U.S. analysis estimated psoriasis in 3.0% of adults aged 20 years or older, equivalent to approximately 7.55 million people.

Only part of this population requires systemic treatment, although conventional severity measures can understate eligibility. An International Psoriasis Council analysis of 2,739 North American patients starting systemic therapy found that 82.7% met systemic-treatment criteria based on body-surface involvement, disease in high-impact locations, or failure of topical treatment.

Patients with psoriasis affecting the face, scalp, genitals, palms, soles, or nails may require advanced treatment even when overall skin involvement is limited. Eligibility is therefore assessed using disease location, quality-of-life impact, and inadequate response to topical therapy, not body-surface area alone.

Psoriatic arthritis further increases systemic-treatment use. A meta-analysis using CASPAR classification criteria estimated psoriatic arthritis in 23.8% of people with psoriasis. Joint involvement favours biologics and oral therapies approved across both dermatology and rheumatology because clinicians can address skin and musculoskeletal disease with one regimen.

 

Topicals Lead Patient Volume, but Advanced Therapies Drive Spending

Topical corticosteroids, vitamin D analogues, combination products, and newer nonsteroidal creams remain central to mild and localized psoriasis. Their broad use does not always translate into sustained adherence. Frequent application, treatment of several body areas, greasy formulations, and the need to continue after visible improvement contribute to inconsistent use.

Phototherapy remains clinically useful but requires repeated treatment sessions over several weeks. Travel, appointment availability, equipment access, and work disruption can make oral or injectable therapy more practical for patients needing long-term control. Home phototherapy reduces travel but still depends on equipment access, training, and insurer coverage.

Systemic biologics and targeted oral drugs reach fewer patients but generate higher recurring expenditure. The German PsoBest registry has enrolled more than 24,500 patients receiving systemic treatment, with follow-up extending to ten years. A 2025 analysis found that biologics accounted for 43.9% of recorded treatment choices.

Biologic use reached 65.9% among patients with psoriasis and psoriatic arthritis, compared with 38.8% among those with skin disease alone. Joint involvement therefore has a direct effect on biologic penetration and treatment duration.

Patient dissatisfaction remains high despite the number of available products. One patient-goal study found that only 7.5% of respondents were extremely satisfied and 8.5% were very satisfied with current treatment. About 69.2% remained dissatisfied with the appearance of their skin, while itch reduction, thinner plaques, and fewer plaques ranked among the leading treatment goals.

An industry-sponsored 2025 survey reported that 50.5% of systemic-treatment-eligible adults preferred an oral option. More than 90% of patients receiving injectable therapy said they would consider switching to an equally effective oral product with a favourable safety profile. The convenience sample is not nationally representative, but it identifies the group most likely to consider icotrokinra and newer TYK2 inhibitors.

 

Icotrokinra Raises Expectations for Oral Psoriasis Therapy

The FDA approved Johnson & Johnson’s icotrokinra, marketed as Icotyde, on March 17, 2026 for adults and adolescents aged 12 years or older who weigh at least 40 kg and have moderate-to-severe plaque psoriasis requiring systemic therapy or phototherapy.

The once-daily oral peptide targets the IL-23 receptor, giving Johnson & Johnson an oral product in a pathway already validated by high-performing injectable biologics. The company can now compete for injection-averse patients without giving up its established position in injectable IL-23 treatment through guselkumab.

Phase III studies reported IGA 0/1 responses of approximately 65% to 71%, PASI 90 responses of about 50% to 58%, and complete PASI 100 clearance in roughly 31% to 32% of patients at week 16.

Icotrokinra also outperformed deucravacitinib in the ICONIC-ADVANCE trials. Oral psoriasis competition is therefore moving beyond comparisons with placebo and apremilast toward direct evaluation against selective TYK2 treatment.

Among patients who achieved PASI 90 at week 24, 84% maintained that response through week 52 with continued treatment, compared with 21% after withdrawal. Median time to response loss after withdrawal was about ten weeks. Continuous treatment supports durable clearance and recurring prescription revenue.

Adolescent approval expands the eligible population beyond adults. In the ICONIC-LEAD adolescent subgroup, 84% achieved clear or almost-clear skin and 70% reached PASI 90 at week 16. Paediatric uptake will depend on payer authorization, long-term safety confidence, and whether clinicians use icotrokinra before phototherapy or older systemic medicines.

Dermatologists may position icotrokinra before biologics in patients who reject injections. Patients already controlled on an IL-17 or IL-23 biologic may have little reason to switch unless oral administration, formulary access, or cost provides a clear advantage.

 

TYK2 Developers Are Competing on Head-to-Head Clearance

Bristol Myers Squibb established the selective TYK2 category with deucravacitinib. In POETYK PSO-1, 58.4% of patients achieved PASI 75 at week 16, compared with 35.1% receiving apremilast and 12.7% receiving placebo. Static physician global assessment scores of clear or almost clear were reached by 53.6%, compared with 32.1% and 7.2%, respectively.

Takeda is attempting to exceed those efficacy levels with zasocitinib. The LATITUDE Phase III studies reported PASI 90 responses of 61.3% and 51.9% at week 16, while PASI 100 reached 33.4% and 25.2%.

More than 90% of week-40 responders who continued zasocitinib maintained PASI 75, PASI 90, or sPGA 0/1 responses through week 60. Durable response will be important when payers compare a daily oral product with biologics administered every eight or twelve weeks.

A separate head-to-head study found zasocitinib statistically superior to deucravacitinib for PASI 100, PASI 90, and complete physician-assessed clearance at week 16. More than 35% of zasocitinib-treated patients achieved PASI 100, over 2.5 times the deucravacitinib rate reported in the study.

Takeda paid approximately USD 4 billion upfront to acquire the Nimbus TYK2 programme. The transaction reflects the revenue expectations attached to an oral therapy capable of improving on the first approved product in the class.

Alumis’ envudeucitinib adds another late-stage competitor. ONWARD1 and ONWARD2 reported week-24 PASI 90 rates of 68.0% and 62.1%, while PASI 100 reached 41.0% and 39.5%. Envudeucitinib remained investigational as of July 2026, but its reported clearance rates place it closer to leading oral candidates than to older systemic tablets.

Several high-efficacy oral launches would pressure formulary placement across deucravacitinib, apremilast, biologics, and biosimilars. Insurers may require patients to use lower-cost oral products before biologics, while manufacturers compete through rebates, safety evidence, paediatric coverage, joint-disease indications, and results in difficult-to-treat areas.

 

Biologics Retain the Highest Clearance and Broadest Clinical Reach

IL-17 and IL-23 inhibitors continue to set the efficacy benchmark for moderate-to-severe plaque psoriasis. A Cochrane network meta-analysis covering 179 randomized trials identified infliximab, bimekizumab, ixekizumab, and risankizumab among the most effective therapies for achieving PASI 90.

Patients with extensive disease, rapid-clearance requirements, or previous systemic-treatment failure are likely to remain on biologics unless oral agents reproduce comparable results over several years.

WHO’s evidence review estimated PASI 90 response proportions of 84.9% for risankizumab, 79.4% to 81.3% for bimekizumab, 78.6% for brodalumab, 77.3% for guselkumab, and 72.0% for ixekizumab. The figures come from indirect comparisons rather than a common head-to-head trial, but they illustrate the efficacy levels oral therapies must approach before clinicians view them as broad biologic substitutes.

Biologics also have an advantage in patients with psoriatic arthritis, axial disease, inflammatory bowel disease, or other immune-mediated conditions. One product that controls both skin and joint symptoms can reduce treatment fragmentation and retain preference over a psoriasis-only therapy.

Long dosing intervals strengthen the IL-23 class. Products administered every eight or twelve weeks after loading may be easier to maintain than daily tablets for some patients. Extended-half-life IL-23 candidates will compete on dosing frequency, onset speed, complete clearance, and durability after longer intervals.

 

Obesity Management Is Entering Psoriasis Treatment Decisions

Obesity and metabolic disease affect inflammation, cardiovascular risk, biologic response, and overall healthcare expenditure. GLP-1 receptor agonists are not established psoriasis medicines, but early studies have reported reduced disease severity among patients receiving them for obesity or type 2 diabetes.

A 2026 National Psoriasis Foundation review found relative PASI reductions of roughly 40% to 80% in published GLP-1 studies. Most studies enrolled only 7 to 48 patients, lasted six months or less, and lacked control groups. The evidence currently supports GLP-1 medicines as metabolic adjuncts rather than substitutes for established psoriasis therapy.

Eli Lilly’s Phase IIIb TOGETHER-PsO study tested tirzepatide with ixekizumab in 274 adults with psoriasis and obesity or overweight. At week 36, 27.1% of patients receiving the combination achieved complete skin clearance and at least 10% weight loss, compared with 5.8% receiving ixekizumab alone.

The combination connects Lilly’s dermatology and obesity portfolios while creating a potential treatment pathway across dermatologists, rheumatologists, endocrinologists, and primary-care physicians.

Payers may limit combined use of two high-cost branded therapies until durable clinical and economic benefits are established. Wider coverage will require evidence that weight loss improves biologic response, reduces treatment escalation, lowers cardiometabolic risk, or offsets costs elsewhere in care.

 

Generalized Pustular Psoriasis Supports Premium Specialist Treatment

Generalized pustular psoriasis differs commercially from chronic plaque psoriasis because acute flares can require emergency treatment and hospitalization. Boehringer Ingelheim’s spesolimab validated IL-36 receptor inhibition and became the first FDA-approved treatment specifically for GPP flares.

In the Effisayil programme, 54% of patients receiving spesolimab had no visible pustules after one week, compared with 6% receiving placebo. Rapid control is particularly valuable in a rare condition associated with severe systemic illness and limited treatment options.

Vanda’s imsidolimab could introduce direct competition in the IL-36 segment. A Phase III study reported clear or almost-clear GPP in 53.3% of patients four weeks after one intravenous dose, compared with 13.3% receiving placebo.

The FDA accepted the biologics licence application in February 2026 and assigned a December 12, 2026 target action date. Approval would give hospitals and specialist centres another acute-flare treatment while increasing competition on pricing, administration, response speed, and flare prevention.

The eligible population is small, but urgent treatment, specialist handling, and limited alternatives support premium pricing.

 

Biosimilars and Reimbursement Will Determine Global Biologic Access

The WHO added adalimumab and ustekinumab to the 2025 Model Lists of Essential Medicines for adult and paediatric psoriasis. National formularies and public procurement bodies can use the decision as a policy reference when expanding advanced-treatment access.

WHO also encouraged quality-assured biosimilars as alternatives to originator medicines. Wider biosimilar use could bring biologic treatment into health systems where originator pricing has restricted access.

A multicentre Latin American study found biologic use in 37.0% of patients with moderate-to-severe psoriasis in Brazil and 27.3% in Chile. Lack of availability or reimbursement affected 22.2% of relevant patients in Brazil and 67.9% in Chile.

Reimbursement differences, rather than clinical eligibility alone, explain much of the regional variation in biologic adoption. Manufacturers entering emerging markets must account for public procurement, specialist availability, diagnostic capacity, and out-of-pocket affordability.

Biosimilars reduce the pricing power of established TNF and IL-12/23 originators. Manufacturers are responding with newer IL-23 products, broader indications, improved injection devices, longer dosing intervals, and payer contracts.

Premium oral products must also compete against discounted biologics rather than against originator list prices. Injection avoidance may not justify a higher price where biosimilars already provide strong clearance at a lower net cost.

 

Safety and Persistence Shape Long-Term Product Value

BADBIR’s 2026 analysis covered 46,770 systemic-treatment episodes among 18,976 patients and recorded an overall serious-infection rate of 27.67 per 1,000 patient-years. Patients with a previous serious infection had a recurrent-infection rate of 78.70 per 1,000 patient-years.

After a serious infection, 67.8% continued the same treatment, 18.2% discontinued, 10.0% switched, and 4.0% postponed therapy. Dermatologists often retain an effective treatment after considering infection severity, disease control, alternative options, and recurrence risk.

Early skin clearance may not translate into sustained treatment use. Declining efficacy, monitoring requirements, adverse events, or poor adherence can prompt switching and shorten treatment duration.

As more oral therapies enter an already crowded biologic market, registry data, comparative safety, and long-term drug persistence will carry greater weight. Products with strong trial results may lose formulary support if real-world use shows frequent discontinuation or switching.

 

Competitive Direction

Johnson & Johnson holds an oral IL-23 position through icotrokinra and an established injectable IL-23 franchise through guselkumab. Bristol Myers Squibb controls the first approved selective TYK2 product, but Takeda’s zasocitinib and Alumis’ envudeucitinib could challenge deucravacitinib on clearance.

AbbVie, Eli Lilly, Novartis, UCB, Amgen, and other immunology companies retain strong positions through IL-23, IL-17, TNF, PDE4, and other systemic therapies. Lilly’s combination of ixekizumab and tirzepatide also links its psoriasis and obesity portfolios.

Biologics are likely to retain their strongest position in severe disease, psoriatic arthritis, and patients requiring the highest probability of PASI 90 or PASI 100. Targeted oral therapies are better positioned among patients who reject injections, fail topical treatment, or want a simpler first systemic option.

Biosimilars will expand access while making price-based displacement more difficult for premium oral medicines. Formulary placement will depend on net price, head-to-head clearance, long-term safety, psoriatic arthritis coverage, dosing convenience, and treatment persistence.

High-efficacy biologics, targeted oral therapies, and lower-cost topicals or biosimilars will serve different patient and payer requirements. Sustained market share will depend less on regulatory approval alone and more on whether products remain effective, affordable, and convenient over years of continuous treatment.

 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 35.13 Billion
Revenue Forecast in 2032	USD 61.08 Billion
Overall Growth Rate	CAGR of 8.1% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Drug Class, By Application, By Route of Administration, By End User, By Geography
By Treatment Type	Topical Therapies, Systemic Therapies, Biologic Therapies, Oral Small-Molecule Therapies, Phototherapy
By Drug Class	Interleukin Inhibitors, TNF Inhibitors, TYK2 Inhibitors, PDE4 Inhibitors, Conventional Immunosuppressants, Retinoids, Corticosteroids, Vitamin D Analogues
By Application	Plaque Psoriasis, Psoriatic Arthritis, Generalized Pustular Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Erythrodermic Psoriasis
By Route of Administration	Oral, Injectable, Topical
By End User	Hospitals, Dermatology Clinics, Specialty Clinics, Homecare Settings, Retail and Specialty Pharmacies
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising prevalence of psoriasis and autoimmune skin disorders, increasing adoption of advanced biologic and targeted therapies, expanding dermatology treatment access and specialty care infrastructure
Customization Option	Available upon request